Aldersgate

Abcam Highlights Successful Execution of Strategic Priorities to Drive Shareholder Value

Retrieved on: 
Tuesday, June 20, 2023
Professional Services, Health, Finance, Research, Science, Biotechnology, Executive, Aldersgate, CREST, FTI Consulting, COVID-19, EGM, EDT, Cyprus Securities and Exchange Commission, PGIP, Russell, Risk, FTI, TSR, BST, Audit, Management, Marketing, Security (finance), Auction, Internet service provider, Proxy, Abcam

Since then, the Company has matured into a fundamentally different business and has successfully executed its Abcam 2.0 strategy.

Key Points: 
  • Since then, the Company has matured into a fundamentally different business and has successfully executed its Abcam 2.0 strategy.
  • With the groundwork now in place, Abcam is set to benefit as sales rise and margins improve.
  • Abcam is successfully executing on its five-year growth strategy to drive long-term value.
  • Abcam’s remuneration program, the Profitable Growth Incentive Plan (PGIP), is aligned with shareholder interests and incentivizes long-term value creation.

Abcam plc files and mails Shareholder Circular calling an Extraordinary General Meeting

Retrieved on: 
Friday, June 16, 2023
Professional Services, Health, Finance, Research, Science, Biotechnology, Cloud, Aldersgate, Investment, CREST, Lead, ERP, COVID-19, Risk, ROCE, UBS, Automation, Annual general meeting, Executive, AIM, Capital market, S. G. Warburg & Co., Mass meeting, Medical tourism, Russell, Knowledge, Growth, War Production Board, TSR, Uncertainty, HSBC, Intellectual property, EGM, Deposit, Antibody, Lazard, CFO, Letter, FTI, FTI Consulting, American depositary receipt, AGM, EDT, Proteomics, Cytokine, Female, BST, Management, Security (finance), Video game, Renewable energy, Pharmaceutical industry, Asset management, Internet service provider, Auction, Abcam, Proxy

Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today filed and mailed a shareholder circular (the “Shareholder Circular”) calling an Extraordinary General Meeting (the “EGM”) to be held on July 12, 2023 at 2:00pm (BST) || 9:00am (EDT).

Key Points: 
  • Abcam plc ("Abcam," "Company," "Group") (Nasdaq: ABCM), a global leader in the supply of life science research tools, today filed and mailed a shareholder circular (the “Shareholder Circular”) calling an Extraordinary General Meeting (the “EGM”) to be held on July 12, 2023 at 2:00pm (BST) || 9:00am (EDT).
  • The Shareholder Circular, and other materials related to the EGM, are available at https://corporate.abcam.com/investors/2023-egm
    The letter sent by Abcam to shareholders in connection with the EGM will accompany the physical mailing of the Shareholder Circular.
  • The nimbleness of Abcam 2.0 means the Company can now make decisions quickly to flex investment as market dynamics change.
  • Dr. Milner’s self-interested campaign to effectuate management control of Abcam is value destructive, expensive and disruptive to Abcam and our shareholders.

BenevolentAI: Notice of Preliminary Results

Retrieved on: 
Thursday, February 16, 2023
Health, Technology, Health Technology, Other Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, FTI Consulting, FTI, Aldersgate, Euronext Amsterdam, BAI, Webcast

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its preliminary results for the year ended 31 December 2022 on Thursday, 16 March 2023.
  • Management will host an in-person briefing for analysts at 09:30 GMT on the day of the results at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London EC1A 4HD).
  • The event will also be accessible via webcast and a recording of the presentation will be made available on the Company’s website shortly afterwards.
  • To register your interest in attending either in person or virtually, please contact FTI Consulting at [email protected] or +44 (0) 20 3727 1000.

BenevolentAI Group: Analyst / Investor Event and Interim Results

Retrieved on: 
Friday, September 16, 2022
University of London, Immunology, Barts and The London School of Medicine and Dentistry, Company, Aldersgate, Technology, Euronext Amsterdam, BAI, St. Bartholomew's, FTI Consulting, Dentistry, University, Webcast, Drug discovery

LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.

Key Points: 
  • LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.
  • The event will be held in person at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom) and will also be accessible via webcast with a presentation recording made available on the Company's website shortly afterwards.
  • At the event, BenevolentAI's executive leadership team will lead sessions about the Company's approach and technology and its positioning within the wider AI drug discovery market, as well as talking about the Company's pipeline and business model.
  • The event will also include an overview of BenevolentAI's interim results for the period ended 30 June 2022.

BenevolentAI Group: Analyst / Investor Event and Interim Results

Retrieved on: 
Friday, September 16, 2022
University of London, Immunology, Barts and The London School of Medicine and Dentistry, Company, Aldersgate, Technology, Euronext Amsterdam, BAI, St. Bartholomew's, FTI Consulting, Dentistry, University, Webcast, Drug discovery

LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.

Key Points: 
  • LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.
  • The event will be held in person at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom) and will also be accessible via webcast with a presentation recording made available on the Company's website shortly afterwards.
  • At the event, BenevolentAI's executive leadership team will lead sessions about the Company's approach and technology and its positioning within the wider AI drug discovery market, as well as talking about the Company's pipeline and business model.
  • The event will also include an overview of BenevolentAI's interim results for the period ended 30 June 2022.

Aldersgate Life Plan Community Presents A Community-Sponsored Holiday Driving Tour

Retrieved on: 
Monday, November 23, 2020
Charlotte metropolitan area, Charlotte, North Carolina, Aldersgate, Shamrock, European culture

Embrace the holiday spirit with a magical driving tour of Aldersgate's beautifully decorated campus and cottages.

Key Points: 
  • Embrace the holiday spirit with a magical driving tour of Aldersgate's beautifully decorated campus and cottages.
  • Thanks to the support of local and national businesses, Aldersgate is able to light the community like never before.
  • Aldersgate invites you to a holiday driving tour of the 231-acre campus on December 5 from 5:30-7:30pm at 3800 Shamrock Drive, Charlotte, NC 28215.
  • Aldersgate is a nonprofit Life Plan community that has been an integral part of the Charlotte, NC, community for more than 70 years.

FTI Consulting Appoints Simon Lewis as a Vice Chairman in EMEA and Global Head of Financial Services in its Strategic Communications Segment

Retrieved on: 
Wednesday, October 23, 2019
FTI Consulting, Management consulting, Business, FCN, 200 Aldersgate, FTI, Aldersgate, Service companies, London

LONDON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Simon Lewis as a Vice Chairman in the Europe, Middle East and Africa (EMEA) region and Global Head of Financial Services in the firms Strategic Communications segment.

Key Points: 
  • LONDON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Simon Lewis as a Vice Chairman in the Europe, Middle East and Africa (EMEA) region and Global Head of Financial Services in the firms Strategic Communications segment.
  • In his new role as a Vice Chairman in the EMEA region, Mr. Lewis will help develop FTI Consultings client relationships across the region and support the firms strategic initiatives.
  • Kevin Hewitt , Chairman of the EMEA region at FTI Consulting, commented, Simon will be an excellent addition to our regional team, which has supported the firms significant growth in EMEA.
  • FTI Consulting, Inc. 200 Aldersgate Aldersgate Street London, EC1A 4HD Investor Contact: Mollie Hawkes +1.617.747.1791 [email protected] Media Contact: Matthew Bashalany +1.617.897.1545 [email protected]